You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
Lixte terminates license agreement with Taipei Medical University
S&P Capital IQ Pro | Powering Your Edge
S&P Capital IQ Pro | Unrivaled Sector Coverage
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.